REVEX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Revex, and when can generic versions of Revex launch?
Revex is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in REVEX is nalmefene hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the nalmefene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Revex
A generic version of REVEX was approved as nalmefene hydrochloride by KNOA PHARMA on February 8th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REVEX?
- What are the global sales for REVEX?
- What is Average Wholesale Price for REVEX?
Summary for REVEX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| DailyMed Link: | REVEX at DailyMed |
US Patents and Regulatory Information for REVEX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | REVEX | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 020459-001 | Apr 17, 1995 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hikma | REVEX | nalmefene hydrochloride | SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS | 020459-002 | Apr 17, 1995 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
